Loading company…
Stately Bio develops machine learning cell imaging technology for regenerative medicine research.
Stately Bio develops a machine learning platform for live-cell, label-free imaging that measures cell identity, behavior and maturation. Its technology supports research and development of stem cell-derived therapies and is intended for research institutions and biotechnology companies. Founded in 2022, the company is based in Palo Alto, US. It raised USD 12.000 mn in Seed funding in May 2025, led by AIX Ventures with participation from Dimension Management and Village Global.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in